Advanced

Shift in business models in pharmaceutical industry

Syrovatka, Tetyana LU (2011) EKHR21 20111
Department of Economic History
Abstract
The following paper is devoted to the research about the shift in business models in the pharmaceutical industry. A fast changing business environment caused by a transformation of technology, communications and business itself, has created a new landscape for the pharmaceutical industry. The old business model built around the blockbuster drug development and production is not efficient any more. Pharmaceutical companies are shifting their business models towards defragmentation and risk aversion. The purpose of this paper is to analyze the shift in business models in the pharmaceutical industry through construction and comparison of the old blockbuster and alternative defragmented business models on the basis of the business model... (More)
The following paper is devoted to the research about the shift in business models in the pharmaceutical industry. A fast changing business environment caused by a transformation of technology, communications and business itself, has created a new landscape for the pharmaceutical industry. The old business model built around the blockbuster drug development and production is not efficient any more. Pharmaceutical companies are shifting their business models towards defragmentation and risk aversion. The purpose of this paper is to analyze the shift in business models in the pharmaceutical industry through construction and comparison of the old blockbuster and alternative defragmented business models on the basis of the business model concept suggested by Osterwalder (2004).For the purpose of the deeper understanding of the researched issue, several in-depth interviews are held with pharmaceutical companies in Skåne region, Sweden. (Less)
Please use this url to cite or link to this publication:
author
Syrovatka, Tetyana LU
supervisor
organization
course
EKHR21 20111
year
type
H1 - Master's Degree (One Year)
subject
keywords
Business model, business model canvas, pharmaceutical industry, blockbuster business model, defragmented business model
language
English
id
1978924
date added to LUP
2011-06-20 11:29:11
date last changed
2011-06-20 11:29:11
@misc{1978924,
  abstract     = {The following paper is devoted to the research about the shift in business models in the pharmaceutical industry. A fast changing business environment caused by a transformation of technology, communications and business itself, has created a new landscape for the pharmaceutical industry. The old business model built around the blockbuster drug development and production is not efficient any more. Pharmaceutical companies are shifting their business models towards defragmentation and risk aversion. The purpose of this paper is to analyze the shift in business models in the pharmaceutical industry through construction and comparison of the old blockbuster and alternative defragmented business models on the basis of the business model concept suggested by Osterwalder (2004).For the purpose of the deeper understanding of the researched issue, several in-depth interviews are held with pharmaceutical companies in Skåne region, Sweden.},
  author       = {Syrovatka, Tetyana},
  keyword      = {Business model,business model canvas,pharmaceutical industry,blockbuster business model,defragmented business model},
  language     = {eng},
  note         = {Student Paper},
  title        = {Shift in business models in pharmaceutical industry},
  year         = {2011},
}